 Jacob Pellinen
Concepts (101)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsies, Partial | 12 | 2025 | 44 | 5.770 |
Why?
| | Epilepsy | 11 | 2025 | 322 | 4.560 |
Why?
| | Seizures | 13 | 2025 | 401 | 2.530 |
Why?
| | Drug Resistant Epilepsy | 2 | 2025 | 82 | 1.480 |
Why?
| | Anticonvulsants | 5 | 2025 | 209 | 1.150 |
Why?
| | Epilepsy, Generalized | 2 | 2021 | 17 | 0.940 |
Why?
| | Neuropsychological Tests | 2 | 2025 | 1014 | 0.820 |
Why?
| | Migraine Disorders | 1 | 2024 | 101 | 0.790 |
Why?
| | Status Epilepticus | 1 | 2022 | 42 | 0.740 |
Why?
| | Artificial Intelligence | 1 | 2024 | 246 | 0.710 |
Why?
| | Malformations of Cortical Development | 1 | 2020 | 13 | 0.700 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2021 | 64 | 0.680 |
Why?
| | Brain Diseases | 1 | 2020 | 136 | 0.630 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 286 | 0.620 |
Why?
| | Cognition | 1 | 2025 | 1122 | 0.540 |
Why?
| | Brain Chemistry | 1 | 2014 | 118 | 0.430 |
Why?
| | Physicians | 1 | 2021 | 859 | 0.410 |
Why?
| | Lipoproteins | 1 | 2014 | 171 | 0.410 |
Why?
| | Fatty Acid Synthases | 1 | 2012 | 24 | 0.390 |
Why?
| | 4-Butyrolactone | 1 | 2012 | 21 | 0.380 |
Why?
| | Delayed Diagnosis | 2 | 2021 | 78 | 0.350 |
Why?
| | Electroencephalography | 4 | 2022 | 399 | 0.350 |
Why?
| | Weight Gain | 1 | 2014 | 509 | 0.340 |
Why?
| | Adaptation, Psychological | 1 | 2014 | 614 | 0.310 |
Why?
| | Humans | 22 | 2025 | 129266 | 0.300 |
Why?
| | Emergency Service, Hospital | 3 | 2024 | 1896 | 0.270 |
Why?
| | Sleep | 2 | 2012 | 684 | 0.270 |
Why?
| | Adult | 9 | 2025 | 35495 | 0.250 |
Why?
| | Syncope | 1 | 2024 | 51 | 0.210 |
Why?
| | Longevity | 1 | 2024 | 152 | 0.200 |
Why?
| | Young Adult | 5 | 2025 | 12391 | 0.200 |
Why?
| | Adolescent | 7 | 2025 | 20313 | 0.190 |
Why?
| | Recurrence | 2 | 2025 | 1005 | 0.180 |
Why?
| | Middle Aged | 6 | 2025 | 31090 | 0.180 |
Why?
| | Neurophysiological Monitoring | 1 | 2020 | 10 | 0.170 |
Why?
| | New York | 1 | 2020 | 128 | 0.170 |
Why?
| | Internet | 1 | 2024 | 615 | 0.170 |
Why?
| | Male | 8 | 2025 | 63512 | 0.160 |
Why?
| | Cohort Studies | 3 | 2025 | 5409 | 0.160 |
Why?
| | Comorbidity | 1 | 2024 | 1544 | 0.160 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 5384 | 0.150 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2019 | 98 | 0.150 |
Why?
| | Microbial Sensitivity Tests | 1 | 2019 | 350 | 0.140 |
Why?
| | Encephalitis | 1 | 2018 | 132 | 0.130 |
Why?
| | Overweight | 1 | 2021 | 531 | 0.130 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 308 | 0.130 |
Why?
| | Tuberculosis | 1 | 2019 | 273 | 0.130 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 309 | 0.120 |
Why?
| | Nerve Tissue Proteins | 1 | 2018 | 569 | 0.110 |
Why?
| | Female | 7 | 2025 | 68551 | 0.110 |
Why?
| | Pandemics | 1 | 2022 | 1481 | 0.110 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2014 | 160 | 0.100 |
Why?
| | Quality of Life | 2 | 2021 | 2687 | 0.100 |
Why?
| | Receptors, Ghrelin | 1 | 2011 | 8 | 0.100 |
Why?
| | Environment | 1 | 2014 | 344 | 0.100 |
Why?
| | Sleep Deprivation | 1 | 2014 | 171 | 0.100 |
Why?
| | Eating | 1 | 2014 | 368 | 0.090 |
Why?
| | Wakefulness | 1 | 2011 | 120 | 0.090 |
Why?
| | Child | 3 | 2024 | 20785 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2024 | 14461 | 0.080 |
Why?
| | Mice, Knockout | 2 | 2014 | 2871 | 0.080 |
Why?
| | Time Factors | 1 | 2020 | 6543 | 0.080 |
Why?
| | Genotype | 1 | 2014 | 1835 | 0.080 |
Why?
| | Lipid Metabolism | 1 | 2012 | 497 | 0.080 |
Why?
| | Enzyme Inhibitors | 1 | 2012 | 827 | 0.070 |
Why?
| | Homeostasis | 1 | 2011 | 605 | 0.070 |
Why?
| | Mice | 3 | 2014 | 16915 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2020 | 10202 | 0.060 |
Why?
| | Animals | 4 | 2025 | 35309 | 0.060 |
Why?
| | Drug Approval | 1 | 2025 | 87 | 0.060 |
Why?
| | Habits | 1 | 2024 | 43 | 0.060 |
Why?
| | Aged | 2 | 2020 | 22032 | 0.060 |
Why?
| | United States Food and Drug Administration | 1 | 2025 | 204 | 0.060 |
Why?
| | Motor Vehicles | 1 | 2023 | 31 | 0.050 |
Why?
| | Documentation | 1 | 2024 | 184 | 0.050 |
Why?
| | Carbamazepine | 1 | 2021 | 19 | 0.050 |
Why?
| | Accidents, Traffic | 1 | 2023 | 184 | 0.050 |
Why?
| | Reference Standards | 1 | 2022 | 176 | 0.050 |
Why?
| | Prospective Studies | 2 | 2025 | 7123 | 0.050 |
Why?
| | Australia | 1 | 2021 | 243 | 0.040 |
Why?
| | Obesity | 1 | 2014 | 2879 | 0.040 |
Why?
| | Reaction Time | 1 | 2022 | 410 | 0.040 |
Why?
| | Monitoring, Physiologic | 1 | 2022 | 265 | 0.040 |
Why?
| | Antibiotics, Antitubercular | 1 | 2019 | 37 | 0.040 |
Why?
| | Data Collection | 1 | 2022 | 647 | 0.040 |
Why?
| | Ophthalmoplegia | 1 | 2018 | 8 | 0.040 |
Why?
| | Rifampin | 1 | 2019 | 85 | 0.040 |
Why?
| | Blepharoptosis | 1 | 2018 | 8 | 0.040 |
Why?
| | Patient Reported Outcome Measures | 1 | 2021 | 372 | 0.040 |
Why?
| | Gait Disorders, Neurologic | 1 | 2018 | 43 | 0.040 |
Why?
| | Coinfection | 1 | 2019 | 131 | 0.040 |
Why?
| | Age Factors | 1 | 2024 | 3140 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2019 | 1839 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2022 | 3080 | 0.030 |
Why?
| | Cognitive Dysfunction | 1 | 2018 | 346 | 0.030 |
Why?
| | Ghrelin | 1 | 2011 | 32 | 0.020 |
Why?
| | Body Temperature | 1 | 2011 | 212 | 0.020 |
Why?
| | United States | 1 | 2025 | 13826 | 0.020 |
Why?
| | Motor Activity | 1 | 2011 | 675 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2018 | 3386 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 5439 | 0.010 |
Why?
|
|
Pellinen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|